3-(m-chlorophenyl)-4-difluoromethoxybenzaldehyde | 1155878-03-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(m-chlorophenyl)-4-difluoromethoxybenzaldehyde
• 英文别名: 3'-chloro-6-difluoromethoxy-biphenyl-3-carbaldehyde；3-(3-Chlorophenyl)-4-(difluoromethoxy)benzaldehyde
• CAS: 1155878-03-7
• 化学式: C₁₄H₉ClF₂O₂
• 分子量: 282.674
• InChiKey: OVWGXBUWLCIHTM-UHFFFAOYSA-N

物化性质

• 沸点：
  371.0±42.0 °C(predicted)
• 密度：
  1.323±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(m-chlorophenyl)-4-difluoromethoxybenzaldehyde 在 sodium tetrahydroborate 、 三溴化磷 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 26.0h， 生成 4-(3-(3-chlorophenyl)-4-difluoromethoxybenzyl)morpholine
  参考文献：
  名称：

  Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect

  摘要：

  Growing evidence confirms the potential of PDE4 inhibitors for the treatment of Parkinson's disease. Our reported PDE4 inhibitors FCPR16 and FCPR03 have displayed neuroprotective effects in SH-SY5Y cells, but have very low oral bioavailability. To access analogues with improved bioavailability, a new series of arylbenzylamine derivatives were designed and synthesized. Preliminary screening results of the series showed that arylbenzylamine derivatives bearing a pyridin-3-amine side chain displayed good inhibitory activities against human PDE4B1 and PDE4D7 isoforms. Moreover, kinetic studies revealed that the most potent compounds 11r and 11s with mid-nanomolar IC50 values partially bind to PDE4B1 (I-max = 93% and 90% respectively). Molecular docking results revealed the possible interactions of compounds 11r and 11s with upstream conserved region 2 (UCR2) of PDE4B1, which illuminate possible reasons for their partial inhibition against PDE4. Using a cell-based model of PD, compounds lir and Us were found to alleviate cellular apoptosis in SH-SY5Y cells induced by MPP+ (1-methyl-4-phenylpyridinium), with this neuroprotective effect being greater than PDE4 inhibitor rolipram. Furthermore, compound 11r displayed nearly sevenfold oral bioavailability (8.20%) than FCPR03 (1.23%). (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.02.026
• 作为产物：
  描述：

  3-bromo-4-(difluoromethoxy)benzaldehyde 、 3-氯苯硼酸 在 palladium diacetate caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3-(m-chlorophenyl)-4-difluoromethoxybenzaldehyde
  参考文献：
  名称：

  BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS

  摘要：

  本发明涉及一类含有至少一个进一步环的联苯化合物的属。这些化合物是PDE4抑制剂，用于治疗和预防中风、心肌梗死和心血管炎症性疾病和紊乱。这些化合物具有一般式Ia、Ib、Ic或Id： 一个特定的实施例是

  公开号：

  US20090136473A1

文献信息

• BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS
  申请人：Singh Jasbir

  公开号：US20090324569A1

  公开（公告）日：2009-12-31

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I: A particular embodiment is

  本发明涉及一类含有至少一个进一步环的双芳基化合物。这些化合物是PDE4抑制剂，可用于治疗和预防中风、心肌梗塞和心血管炎症性疾病和障碍。这些化合物具有一般式I：其中，一种特定的实施例为：
• BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
  申请人：SINGH Jasbir

  公开号：US20120213758A1

  公开（公告）日：2012-08-23

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: A particular embodiment is

  本发明涉及一类含有至少一个进一步环的双芳基化合物。这些化合物是PDE4抑制剂，可用于治疗和预防中风、心肌梗死和心血管炎症性疾病和紊乱。这些化合物的一般式为Ia、Ib、Ic或Id：其中一种特定的实施例为：
• Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
  申请人：Decode Genetics EHF

  公开号：EP2628727A2

  公开（公告）日：2013-08-21

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: or salt thereof, in particular a pharmaceutically acceptable salt thereof.

  本发明涉及一种含有至少一个附加环的双芳基化合物。这些化合物是 PDE4 抑制剂，可用于治疗和预防中风、心肌梗塞和心血管炎症性疾病和紊乱。这些化合物具有通式 Ia、Ib、Ic 或 Id： 或其盐，特别是其药学上可接受的盐。
• Biaryl PDE4 inhibitors for treating inflammation
  申请人：Decode Genetics EHF

  公开号：EP2674417A2

  公开（公告）日：2013-12-18

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I:

  本发明涉及一种含有至少一个附加环的双芳基化合物。这些化合物是 PDE4 抑制剂，可用于治疗和预防中风、心肌梗塞和心血管炎症性疾病和紊乱。这些化合物具有通式 I：
• BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION
  申请人：Decode Genetics EHF

  公开号：EP2222638A2

  公开（公告）日：2010-09-01